Literature DB >> 16884316

Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Jason A Roberts1, Jeffrey Lipman.   

Abstract

Treatment of sepsis remains a significant challenge with persisting high mortality and morbidity. Early and appropriate antibacterial therapy remains an important intervention for such patients. To optimise antibacterial therapy, the clinician must possess knowledge of the pharmacokinetic and pharmacodynamic properties of commonly used antibacterials and how these parameters may be affected by the constellation of pathophysiological changes occurring during sepsis. Sepsis, and the treatment thereof, increases renal preload and, via capillary permeability, leads to 'third-spacing', both resulting in higher antibacterial clearances. Alternatively, sepsis can induce multiple organ dysfunction, including renal and/or hepatic dysfunction, causing a decrease in antibacterial clearance. Aminoglycosides are concentration-dependent antibacterials and they display an increased volume of distribution (V(d)) in sepsis, resulting in decreased peak serum concentrations. Reduced clearance from renal dysfunction would increase the likelihood of toxicity. Individualised dosing using extended interval dosing, which maximises the peak serum drug concentration (C(max))/minimum inhibitory concentration ratio is recommended. Beta-lactams and carbapenems are time-dependent antibacterials. An increase in V(d) and renal clearance will require increased dosing or administration by continuous infusion. If renal impairment occurs a corresponding dose reduction may be required. Vancomycin displays predominantly time-dependent pharmacodynamic properties and probably requires higher than conventionally recommended doses because of an increased V(d) and clearance during sepsis without organ dysfunction. However, optimal dosing regimens remain unresolved. The poor penetration of vancomycin into solid organs may require alternative therapies when sepsis involves solid organs (e.g. lung). Ciprofloxacin displays largely concentration-dependent kill characteristics, but also exerts some time-dependent effects. The V(d) of ciprofloxacin is not altered with fluid shifts or over time, and thus no alterations of standard doses are required unless renal dysfunction occurs. In order to optimise antibacterial regimens in patients with sepsis, the pathophysiological effects of systemic inflammatory response syndrome need consideration, in conjunction with knowledge of the different kill characteristics of the various antibacterial classes. In conclusion, certain antibacterials can have a very high V(d), therefore leading to a low C(max) and if a high peak is needed, then this would lead to underdosing. The V(d) of certain antibacterials, namely aminoglycosides and vancomycin, changes over time, which means dosing may need to be altered over time. Some patients with serum creatinine values within the normal range can have very high drug clearances, thereby producing low serum drug levels and again leading to underdosing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884316     DOI: 10.2165/00003088-200645080-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  207 in total

1.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.

Authors:  W J Munckhof; M L Grayson; J D Turnidge
Journal:  J Antimicrob Chemother       Date:  1996-04       Impact factor: 5.790

3.  Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.

Authors:  J Lipman; S C Wallis; C Rickard
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  A Bayesian feedback method of aminoglycoside dosing.

Authors:  M E Burton; D C Brater; P S Chen; R B Day; P J Huber; M R Vasko
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

Review 5.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

6.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

7.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

9.  Cefepime versus cefpirome: the importance of creatinine clearance.

Authors:  Jeffrey Lipman; Steven C Wallis; Robert J Boots
Journal:  Anesth Analg       Date:  2003-10       Impact factor: 5.108

10.  Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity.

Authors:  Keith M Olsen; Maria I Rudis; Jill A Rebuck; Jill Hara; Dave Gelmont; Ramin Mehdian; Casey Nelson; Mark E Rupp
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

View more
  56 in total

1.  Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.

Authors:  Jason A Roberts; Jonathan Field; Adam Visser; Rosemary Whitbread; Mandy Tallot; Jeffrey Lipman; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 3.  Urosepsis--Etiology, Diagnosis, and Treatment.

Authors:  Nici Markus Dreger; Stephan Degener; Parviz Ahmad-Nejad; Gabriele Wöbker; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2015-12-04       Impact factor: 5.594

4.  Chitosan sponges to locally deliver amikacin and vancomycin: a pilot in vitro evaluation.

Authors:  Scott P Noel; Harry S Courtney; Joel D Bumgardner; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

Review 5.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 6.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

8.  Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF).

Authors:  Deirdre M D'Arcy; Owen I Corrigan; Evelyn Deasy; Caitríona M Gowing; Maria B Donnelly
Journal:  Eur J Clin Pharmacol       Date:  2014-11-26       Impact factor: 2.953

9.  Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.

Authors:  I Martin-Loeches; T Lisboa; A Rodriguez; C Putensen; D Annane; J Garnacho-Montero; M I Restrepo; J Rello
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

10.  Short acting insulin analogues in intensive care unit patients.

Authors:  Federico Bilotta; Carolina Guerra; Rafael Badenes; Simona Lolli; Giovanni Rosa
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.